Germany Drug Forecast and Market Analysis to 2022 - 0 views
-
Matilde Fernandes on 13 Dec 13The German chronic heart failure (CHF) therapeutics market was worth approximately USD 484.7 million in 2012, with a projected compound annual growth rate (CAGR) of 2.4%, to reach a total of USD 614.8 million in 2022. The launch of Novartis' novel combination drug, LCZ-696 in 2015 will mark the first entrance of a novel branded CHF drug in the past five years, boosting the overall market size considerably till 2022.